Hepion Pharmaceuticals, Inc. (CTRVP) — 10-Q Filings
All 10-Q filings from Hepion Pharmaceuticals, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Hepion Pivots to Diagnostics, Cuts R&D Spend, Boosts Cash
— Nov 12, 2025 Risk: high
Hepion Pharmaceuticals, Inc. (CTRVP) reported a net loss of $7,620,965 for the nine months ended September 30, 2025, a significant improvement from the $11,644, -
Hepion Pivots to Diagnostics, Divests Rencofilstat Amidst Rising Losses
— Aug 14, 2025 Risk: high
Hepion Pharmaceuticals, Inc. (CTRVP) reported a net loss of $7,148,459 for the six months ended June 30, 2025, a significant increase from the $6,779,018 net lo -
Hepion Pharmaceuticals Files Q1 2025 10-Q
— May 19, 2025 Risk: medium
Hepion Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly ContraVir Pharmaceuticals, Inc., is based in Edison, NJ. -
Hepion Pharmaceuticals Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
Hepion Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as ContraVir Pharmaceuticals, Inc., is based i -
Hepion Pharmaceuticals Files Q2 2024 10-Q
— Aug 13, 2024 Risk: medium
Hepion Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business -
Hepion Pharmaceuticals Files Q1 2024 10-Q
— May 21, 2024 Risk: medium
Hepion Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2024. The company, formerly known as ContraVir Pharmaceuticals, Inc., reported its f
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX